Investment Rating - The investment rating for the company is "Buy" indicating an expected return exceeding 10% relative to the CSI 300 index over the next six months [4][18]. Core Insights - The company achieved a stable revenue of 620 million yuan in H1 2025, reflecting a year-on-year growth of 1.28%, while the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan due to increased R&D expenses and competition in the animal health industry [1][2]. - The company is leading in the development of African swine fever vaccines, having established an integrated R&D platform and received the first clinical trial approval for its subunit vaccine in July 2025 [2][3]. - The company is focused on innovation-driven growth, with R&D expenses amounting to 84 million yuan, representing 13.51% of its revenue. It has made significant advancements in various vaccine technologies and new veterinary drugs [3][4]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 620 million yuan, a slight increase of 1.28% year-on-year. However, net profit fell to 60.42 million yuan, a decline of 50.84% due to rising R&D costs and increased competition leading to lower product prices and gross margin [1]. - The gross margin for H1 2025 was 52.24%, down 5.68 percentage points from the previous year [1]. Vaccine Development - The company is at the forefront of African swine fever vaccine development, with multiple technological routes being explored, including gene deletion vaccines and mRNA vaccines. The subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs [2]. - The company has also made strides in developing new vaccines for cats and multi-valent vaccines for cattle, with several clinical trial approvals obtained [3]. R&D and Innovation - The company emphasizes R&D innovation, with a focus on addressing the pain points of livestock customers. The R&D investment in H1 2025 was 84 million yuan, which is 13.51% of its revenue [3]. - Notable achievements include the approval of an mRNA vaccine for feline infectious peritonitis and a multi-valent inactivated vaccine for cattle diseases [3].